Flu COVID Vaccine Views
Part of paid clinical trials in Washington D.C., District of Columbia.
- Sponsor
- George Washington University
- Study ID
- NCT07871448
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- COVID-19
- Influenza
- Vaccination Willingness
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 89 Years
- Healthy Volunteers
- Accepted
Interventions
- Survey — OTHEROne-time RedCAP electronic survey on the willingness of healthcare workers to receive a combination influenza/COVID-19 vaccine and factors that might influence this decision.
Study Details
This study addresses a critical evidence gap relevant to implementation strategies for combination vaccines in health care settings. This study will specifically investigate healthcare worker (HCWs) attitudes around and willingness to receive combination influenza/COVID-19 vaccines. Findings will identify determinants of hesitancy and acceptance among HCWs and support effective rollout strategies and communication approaches. Cross-sectional surveys and qualitative interviews will be conducted with healthcare workers to characterize HCW willingness to be vaccinated and to identify demographic, attitudinal, and structural predictors of vaccination.
Key Dates
- First listed
- Oct 13, 2026
- Start date
- Oct 1, 2026
- Status verified
- Oct 2026
- Primary completion
- Sep 30, 2027
- Completion
- Apr 1, 2028
Study Design
- Enrollment
- 550 participants (estimated)
Primary Outcome Measure
Proportion of health care workers (HCWs) who indicate that they would "definitely" or "probably" receive a combination influenza and COVID-19 vaccine. [ Time Frame: Day 1 ]
Central Contacts
- Daniel Park, PhD202-994-0218
- Annie Roberts610-283-4402
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Children's National Hospital | Washington D.C. | District of Columbia | 20020 | Sarah Schaffer DeRoo, MD (PRINCIPAL_INVESTIGATOR) |
| George Washington University | Washington D.C. | District of Columbia | 20037 | David Diemert, MD (SUB_INVESTIGATOR) Daniel Park, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Washington D.C., DC
Related Studies
- EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe DiseasePHASE3 · Recruiting · Pfizer · Los Angeles, California
- A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)PHASE3 · Recruiting · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Anniston, Alabama
- Viral Infections in Healthy and Immunocompromised HostsRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Screening for LID Clinical Studies Unit Healthy Volunteer ProtocolsRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland